Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma

Mesothelioma is a rare and aggressive malignancy with a poor prognosis. Without treatment, the median survival time ranges between six and nine months [1]. As the diagnosis usually is made at an advanced stage most patients are not eligible for surgery and designated for palliative systemic treatment [2]. Treatment in first-line with a combination of platinum and pemetrexed resulted in a median survival benefit of three months [3]. The addition of bevacizumab resulted in an additional survival benefit of nearly three months [4].

Source: Lung Cancer - December 13, 2023 Category: Cancer & Oncology Authors: D.W. Dumoulin, L.H. Douma, M.M. Hofman, V. van der Noort, R. Cornelissen, C.J. de Gooijer, J.A. Burgers, J.G.J.V. Aerts Source Type: research